Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-10-10
2006-10-10
Wilson, James (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023500, C536S023600, C536S023700, C536S024100, C536S024500, C536S025300, C536S025310
Reexamination Certificate
active
07119184
ABSTRACT:
Modified oligonucleotides containing both A-form conformation geometry and B-from conformation geometry nucleotides are disclosed. The B-form geometry allows the oligonucleotide to serve as substrates for RNase H when bound to a target nucleic acid strand. The A-form geometry imparts properties to the oligonucleotide that modulate binding affinity and nuclease resistance. By utilizing C2′ endo sugars or O4′ endo sugars, the B-form characteristics are imparted to a portion of the oligonucleotide. The A-form characteristics are imparted via use of either 2′-O-modified nucleotides that have 3′ endo geometries or use of end caps having particular nuclease stability or by use of both of these in conjunction with each other.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan et al.
patent: 4381344 (1983-04-01), Rideout et al.
patent: 4689320 (1987-08-01), Kaji
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5004810 (1991-04-01), Draper
patent: 5013830 (1991-05-01), Ohtsuka et al.
patent: 5134066 (1992-07-01), Rogers et al.
patent: 5166195 (1992-11-01), Ecker
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5212295 (1993-05-01), Cook
patent: 5214135 (1993-05-01), Srivastava et al.
patent: 5242906 (1993-09-01), Pagano et al.
patent: 5245022 (1993-09-01), Weis et al.
patent: 5248670 (1993-09-01), Draper et al.
patent: 5334711 (1994-08-01), Sproat et al.
patent: 5442049 (1995-08-01), Anderson et al.
patent: 5457189 (1995-10-01), Crooke et al.
patent: 5466786 (1995-11-01), Buhr et al.
patent: 5514577 (1996-05-01), Draper et al.
patent: 5514788 (1996-05-01), Bennett et al.
patent: 5523389 (1996-06-01), Ecker et al.
patent: 5580767 (1996-12-01), Cowsert et al.
patent: 5582972 (1996-12-01), Lima et al.
patent: 5582986 (1996-12-01), Monia et al.
patent: 5591600 (1997-01-01), Ecker
patent: 5591623 (1997-01-01), Bennett et al.
patent: 5591720 (1997-01-01), Anderson et al.
patent: 5607923 (1997-03-01), Cook et al.
patent: 5620963 (1997-04-01), Cook et al.
patent: 5627053 (1997-05-01), Usman et al.
patent: 5639647 (1997-06-01), Usman et al.
patent: 5639649 (1997-06-01), Almond et al.
patent: 5658731 (1997-08-01), Sproat et al.
patent: 5658891 (1997-08-01), Draper et al.
patent: 5661134 (1997-08-01), Cook et al.
patent: 5670633 (1997-09-01), Cook et al.
patent: 5672695 (1997-09-01), Eckstein et al.
patent: 5681747 (1997-10-01), Boggs et al.
patent: 5681944 (1997-10-01), Crooke et al.
patent: 5698687 (1997-12-01), Eckstein et al.
patent: 5817635 (1998-10-01), Eckstein et al.
patent: 5859221 (1999-01-01), Cook et al.
patent: 5877309 (1999-03-01), McKay et al.
patent: 5955443 (1999-09-01), Bennett et al.
patent: 5985558 (1999-11-01), Dean et al.
patent: 6111094 (2000-08-01), Bennett et al.
patent: 6300491 (2001-10-01), Bennett et al.
patent: 6307040 (2001-10-01), Cook et al.
patent: 6369209 (2002-04-01), Manoharan et al.
patent: 1 205 021 (1986-05-01), None
patent: 2017369 (1990-05-01), None
patent: 39 15462 (1990-06-01), None
patent: 41 10085 (1992-10-01), None
patent: 0 260 032 (1987-08-01), None
patent: 0 287 313 (1988-10-01), None
patent: 339 842 (1989-11-01), None
patent: 0 417 999 (1991-03-01), None
patent: 0 552 178 (1997-01-01), None
patent: WO 89/12060 (1989-12-01), None
patent: WO 90/15814 (1990-12-01), None
patent: WO 91/06556 (1991-05-01), None
patent: WO 91/10671 (1991-07-01), None
patent: WO 91/14696 (1991-10-01), None
patent: WO 91/15499 (1991-10-01), None
patent: WO 92/03568 (1992-03-01), None
patent: WO 92/07065 (1992-04-01), None
patent: WO 94/08003 (1994-04-01), None
patent: WO 98/29124 (1998-07-01), None
Damha et al., Bioconjugate Chem., vol. 10, 1999, pp. 299-305.
Griffey, R.H., et al., “2′-O-aminopropyl ribonucleotides: A zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides,”J. Med. Chem.,1996, 39, 5100-5109.
EPO Communication—Supplementary European Search Report dated Jul. 24, 2002 (EP 00928716.0).
Copy of the European Partial Search Report dated Oct. 27, 2003 (EP 03 07 6286).
Czuchajowski, L., et al., “Porphyrinyl-uridines as the first water soluble porphyrinyl-nucleosides,”Tetrahedron Letters,Dec. 16, 1991, 32, XP 000247164, pp. 7511 and 7512.
Goodchild, J., “Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties,”Bioconjugate Chemistry,May/Jun. 1990, 1(3), 165-187.
Manoharan, M., et al., “Novel functionalization of the sugar moiety of nucleic acids for multiple labeling in the minor groove,”Tetrahedron Letters,1991, 32(49), 717-7174.
Tung, C.-H., et al., “Preparation of oligonucleotide-peptide conjugates,”Bioconjugate Chemistry,Nov./Dec. 1991, 2(6), XP 000235497, 464-465.
Abe, A. et al., “Conformational Energies and the Random-Coil Dimensions and Dipole Moments of Polyoxides CH3O[(CH2)yO]×CH3,”J. Am. Chem. Soc.,1976, 6468-6476.
Albert, P.R. et al., “Antisense knockouts: molecular scalpels for the dissection of signal transduction”,Trends Pharmacol. Sci.,1994, 15, 250-254.
Altmann, K. et al., “Second Generation Antisense Oligonucleotides-Inhibition of Pkc-1 And c-RAF Kinase Expression by Chimeric Oligonucleotides Incorporating 6-Substituted Carbocyclic Nucleosides and 2′-O-Ethylene Glycol Substituted Ribonucleosides,”Nucleosides&Nucleotides,1997, 16(7-9), 917-926.
Altmann, K. et al., “Second-Generation Antisense Oligonucleotides: Structure-Activity Relationships and the Design of Improved Signal-Transduction Inhibitors”,Biochem. Soc. Trans.,1996, 24, 630-637.
Altmann, K. et al., “Second Generation Antisense Oligonucleotides: From Nuclease Resistance to Biological Efficacy in Animals,”Chimia,1996, 50, 168-176.
Baker, B.F. et al., “2′-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells”,J. Biol. Chem.,1997, 272, 11994-12000.
Beal, P. A. et al., “Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix Formation,”Science,1991, 251, 1360-1363.
Beaucage, S.L. et al., “Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach”,Tetrahedron,1992, 48, 2223-2311.
Berger et al., “Crystal structures of B-DNA with incorporated 2′-deoxy-2′-fluoro-arabino-furanosyl thymines: implications of conformational preorganization for duplex stability,”Nucl. Acids Res.,1998, 26(10), 2473-2480.
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy,15th Edition, Rahway, N.J., 1987, 2263-2277.
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy,15th Edition, Rahway, N.J., 1987, 2283-2287.
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy,15th Edition, Rahway, N.J., 1987, 2286-2293.
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy,15thEdition, Rahway, N.J., 1987, 2301-2310.
Bernhard, E.J. et al., “Direct Evidence Linking Expression of Matrix Metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells,”Proc. Natl. Acad. Sci. USA,1994, 91, 4293-4297.
Birkedal-Hansen, H. et al., “Proteolytic Remodeling of Extracellular Matrix,”Curr. Op. Cell Biol.,1995, 7, 728-735.
Bock, L. C. et al., “Selection of Single-Stranded DNA Molecules that Bind and Inhibit Human Thrombin,”Nature,1992, 355, 564-566.
Böggemeyer, E. et al., “Borrelia Burgdorferi Upregulates the Adhesion Molecules E-selectin, P-selectin, ICAM-1 and VCAM-1 on Mouse Endothelioma Cells in vitro,”Cell Adhes. Commun.,1994, 2, 145-157.
Conte, M. R. “Confirmational Properties and Thermodynamics of the RNA Duplex r(CGCAAAUUUGCG)2: Comparison with the DNA Analogue d(CGCAAATTTGCG)2,”Nucl. Acids Res.,1997, 25(13), 2677-2634.
Cornell, W.D. et al., “A Second Generation Force Field for the Simula
Cook Phillip Dan
Kawasaki Andrew M.
Manoharan Muthiah
Mohan Venkatraman
Isis Patent Department Woodcock Washburn LLP
Isis Pharmaceuticals , Inc.
Krishnan Ganapathy
Wilson James
LandOfFree
Oligonucleotides having A-DNA form and B-DNA form... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotides having A-DNA form and B-DNA form..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotides having A-DNA form and B-DNA form... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3636833